Balloon-Expandable TAVI Valves Outlast Self-Expandable Ones in Large Aortic Annulus Patients
A 7-year Japanese registry study finds balloon-expandable TAVI valves significantly reduce bioprosthetic valve failure vs. self-expandable devices in large aortic annuli.
Summary
Transcatheter aortic valve implantation (TAVI) has become the standard approach for aortic stenosis, but questions remain about which valve type lasts longer in patients with a large aortic annulus. This retrospective analysis of over 1,000 patients from a Japanese multicenter registry followed outcomes for up to 7 years. While survival rates were similar between balloon-expandable and self-expandable valves, the balloon-expandable type showed a significantly lower rate of bioprosthetic valve failure after propensity-score matching. This matters for aging adults with aortic stenosis — a common age-related condition — because longer valve durability could reduce the need for repeat procedures and improve long-term quality of life.
Detailed Summary
Aortic stenosis is one of the most prevalent age-related cardiac conditions, and TAVI has transformed its treatment by offering a less invasive alternative to open-heart surgery. However, as TAVI is increasingly used in younger and lower-risk patients expected to live longer, valve durability has become a central concern — particularly for those with anatomically challenging large aortic annuli, where valve sizing and seating are more complex.
This retrospective study from the Japanese OCEAN-TAVI registry analyzed 1,054 patients who underwent transfemoral TAVI for tricuspid aortic stenosis with a large aortic annulus (annulus area greater than 430 mm²). Patients received either a balloon-expandable valve (SAPIEN 3, Edwards LifeSciences) or a self-expandable valve (Evolut R/PRO, Medtronic). Propensity score matching produced 218 comparable pairs to reduce confounding.
Over a 7-year follow-up, overall survival was statistically similar between the two groups — roughly 53% vs. 70% cumulative mortality at 7 years in the matched cohort, a difference that did not reach significance. However, bioprosthetic valve failure — encompassing structural deterioration, hemodynamic dysfunction, or reintervention — told a different story. After propensity score matching, the balloon-expandable group showed a significantly lower valve failure rate: 3.3 versus 9.9 events per 1,000 patient-years, a near-threefold difference that reached statistical significance.
For patients and clinicians, this finding has meaningful real-world implications. Valve failure in TAVI patients often means additional high-risk procedures, reduced quality of life, and greater healthcare burden — outcomes that matter profoundly in older adults already managing multiple comorbidities.
Caveats are notable: this is a retrospective, observational registry study from Japan, and the summary here is based on the abstract alone. Differences in operator experience, patient selection, and unmeasured confounders may influence results despite propensity matching. Generalizability to Western populations warrants further study.
Key Findings
- Balloon-expandable TAVI valves had nearly 3x lower bioprosthetic valve failure rate vs. self-expandable valves in large aortic annulus patients after propensity matching.
- 7-year survival rates were statistically comparable between balloon-expandable and self-expandable TAVI groups.
- Bioprosthetic valve failure rate: 3.3 vs. 9.9 events per 1,000 patient-years, a statistically significant difference (P=0.017).
- Results were derived from a large multicenter Japanese registry of 1,054 TAVI patients with large aortic annuli (area >430 mm²).
- Valve durability — not just survival — is an increasingly critical outcome as TAVI expands to longer-lived, lower-risk patients.
Methodology
Retrospective analysis of 1,054 patients from the multicenter OCEAN-TAVI registry in Japan, comparing balloon-expandable (SAPIEN 3) and self-expandable (Evolut R/PRO) TAVI valves in patients with large aortic annulus (>430 mm²). Propensity score matching yielded 218 pairs to control for baseline differences. Primary endpoints were 7-year cumulative all-cause mortality and bioprosthetic valve failure rates.
Study Limitations
This is a retrospective observational study, limiting causal inference despite propensity score matching; unmeasured confounders and operator-level variation could influence outcomes. The study is based in Japan, and anatomical, patient-mix, and practice differences may limit generalizability to other populations. This summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: